Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein

Abstract Although second-generation therapies like abiraterone (ABI) and enzalutamide (ENZ) benefit patients with castration-resistant prostate cancer (CRPC), drug resistance frequently occurs, eventually resulting in therapy failure. In this study, we used two libraries, FDA-approved drug library a...

Full description

Bibliographic Details
Main Authors: Ying Zhang, Wei Wei, Changying Li, Siyuan Yan, Shanshan Wang, Shudong Xiao, Chenchen He, Jing Li, Zhi Qi, Benyi Li, Kuo Yang, Changlin Li
Format: Article
Language:English
Published: Nature Publishing Group 2022-12-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-05490-5

Internet

https://doi.org/10.1038/s41419-022-05490-5

Similar Items